Save Product
Product Details
Synonyms
EGFRvIII
Source
Human EGFRvIII, His Tag (EGI-H52H4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 40.5 kDa. The protein migrates as 55-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human EGFRvIII, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) is more than 95% and the molecular weight of this protein is around 50-70 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
Protocol
Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Cetuximab with a linear range of 0.1-1 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-EGF R antibody captured on Protein A Chip can bind Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) with an affinity constant of 1.42 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-FACS
2e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 3 μg/mL of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
Recent Advances
Drug Development Progress- English Name：
Epidermal growth factor receptor variant III
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
14 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
